Artiva Biotherapeutics, Inc. Common Stock (ARTV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Artiva Biotherapeutics, Inc. Common Stock stock (ARTV) is currently trading at $5.23. Artiva Biotherapeutics, Inc. Common Stock PS ratio (Price-to-Sales) is 8.11. Analyst consensus price target for ARTV is $17.00. WallStSmart rates ARTV as Sell.
- ARTV PE ratio analysis and historical PE chart
- ARTV PS ratio (Price-to-Sales) history and trend
- ARTV intrinsic value — DCF, Graham Number, EPV models
- ARTV stock price prediction 2025 2026 2027 2028 2029 2030
- ARTV fair value vs current price
- ARTV insider transactions and insider buying
- Is ARTV undervalued or overvalued?
- Artiva Biotherapeutics, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- ARTV Piotroski F-Score and Altman Z-Score
- ARTV analyst price target and Smart Rating
Artiva Biotherapeutics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Artiva Biotherapeutics, Inc. Common Stock (ARTV) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Artiva Biotherapeutics, Inc. Common Stock (ARTV) Key Strengths (2)
Trading at 1.20x book value, attractively priced
68.69% held by institutions, strong professional interest
Supporting Valuation Data
Artiva Biotherapeutics, Inc. Common Stock (ARTV) Areas to Watch (4)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 8.1x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Artiva Biotherapeutics, Inc. Common Stock (ARTV) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 8.0/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (1.20) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (8.11) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -56.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -56.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ARTV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ARTV's Price-to-Sales ratio of 8.11x trades at a deep discount to its historical average of 47.73x (59th percentile). The current valuation is 98% below its historical high of 530.36x set in Feb 2026, and 637% above its historical low of 1.1x in Jun 2025. Over the past 12 months, the PS ratio has expanded from ~2.4x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Artiva Biotherapeutics, Inc. Common Stock (ARTV) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Artiva Biotherapeutics, Inc. Common Stock operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -15M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Artiva Biotherapeutics, Inc. Common Stock.
Bottom Line
Artiva Biotherapeutics, Inc. Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Artiva Biotherapeutics, Inc. Common Stock(ARTV)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Artiva Biotherapeutics, Inc. is an innovative biotechnology company focused on developing next-generation cell therapies for cancer. Leveraging a proprietary platform to enhance natural killer (NK) cell therapies, Artiva is advancing an extensive pipeline targeting a variety of hematologic and solid tumors. The company's commitment to scientific excellence and strategic partnerships positions it as a key player in the dynamic field of immuno-oncology. As it moves forward with clinical development of its promising therapeutic candidates, Artiva aims to transform cancer treatment and significantly improve patient outcomes.